Literature DB >> 10873667

COX-2 inhibition prevents insulin-dependent diabetes in low-dose streptozotocin-treated mice.

T Tabatabaie1, A M Waldon, J M Jacob, R A Floyd, Y Kotake.   

Abstract

Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease believed to be caused by an inflammatory process in the pancreas leading to selective destruction of the beta cells. Inducible cyclooxygenase (COX-2) is expressed under inflammatory conditions and its product prostaglandin E(2) (PGE(2)) is an important inflammation mediator. We report here that administration of the selective COX-2 inhibitor NS-398 prevents the onset of diabetes in mice brought on by multiple low-doses of streptozotocin (STZ). Histological observations indicated that STZ-mediated destruction of beta cells was prevented by NS-398 treatment. Delayed (day 3) administration of NS-398 was also protective in this model. No protective effect was observed when NS-398 was administered prior to a high, toxic dose of STZ. These results demonstrate the critical importance of COX-2 activity in autoimmune destruction of beta cells, and point to the fact that COX-2 inhibition can potentially develop into a preventive therapy against IDDM. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873667     DOI: 10.1006/bbrc.2000.2959

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Macrophage migration inhibitory factor deficiency protects pancreatic islets from cytokine-induced apoptosis in vitro.

Authors:  I Stojanovic; T Saksida; I Nikolic; F Nicoletti; S Stosic-Grujicic
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

2.  Activation of AMPK improves inflammation and insulin resistance in adipose tissue and skeletal muscle from pregnant women.

Authors:  Stella Liong; Martha Lappas
Journal:  J Physiol Biochem       Date:  2015-09-25       Impact factor: 4.158

Review 3.  Eicosanoids, β-cell function, and diabetes.

Authors:  Pengcheng Luo; Mong-Heng Wang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-07-03       Impact factor: 3.072

4.  Increased expression of cyclooxygenase-2 in human pancreatic islets treated with high glucose or ligands of the advanced glycation endproduct-specific receptor (AGER), and in islets from diabetic mice.

Authors:  N Shanmugam; I T Todorov; I Nair; K Omori; M A Reddy; R Natarajan
Journal:  Diabetologia       Date:  2005-12-10       Impact factor: 10.122

5.  Prostaglandin E2 regulates Foxo activity via the Akt pathway: implications for pancreatic islet beta cell dysfunction.

Authors:  Z X Meng; J X Sun; J J Ling; J H Lv; D Y Zhu; Q Chen; Y J Sun; X Han
Journal:  Diabetologia       Date:  2006-10-11       Impact factor: 10.122

6.  Transcription factor Ets-1 inhibits glucose-stimulated insulin secretion of pancreatic β-cells partly through up-regulation of COX-2 gene expression.

Authors:  Xiong-Fei Zhang; Yi Zhu; Wen-Biao Liang; Jing-Jing Zhang
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

Review 7.  Light regulation of the insulin receptor in the retina.

Authors:  Raju V S Rajala; Robert E Anderson
Journal:  Mol Neurobiol       Date:  2003-10       Impact factor: 5.590

Review 8.  Role of increased ROS dissipation in prevention of T1D.

Authors:  Jing Chen; Aaron M Gusdon; Terri C Thayer; Clayton E Mathews
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

9.  Commonalities of genetic resistance to spontaneous autoimmune and free radical--mediated diabetes.

Authors:  Jing Chen; Ying Lu; Chul-Ho Lee; Renhua Li; Edward H Leiter; Clayton E Mathews
Journal:  Free Radic Biol Med       Date:  2008-07-31       Impact factor: 7.376

10.  The ETS-Domain Transcription Factor Elk-1 Regulates COX-2 Gene Expression and Inhibits Glucose-Stimulated Insulin Secretion in the Pancreatic β -Cell Line INS-1.

Authors:  Xiong-Fei Zhang; Yi Zhu; Wen-Biao Liang; Jing-Jing Zhang
Journal:  Int J Endocrinol       Date:  2013-06-02       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.